Close Menu

NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Wednesday that its third quarter revenues rose 74 percent year over year, thanks largely to a 6 percent increase in test volume for its AlloMap non-invasive blood test for heart transplant patients.

For the three months ended Sept. 30, the diagnostics company said revenues rose to $12.5 million from $7.2 million a year earlier, beating the average Wall Street analyst estimate of $11.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Time magazine looks into how liquid biopsies are changing cancer care.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.